Comparative Pharmacology
Head-to-head clinical analysis: ANZEMET versus ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANZEMET versus ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER.
ANZEMET vs ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, inhibiting emesis.
Ondansetron is a selective serotonin 5-HT3 receptor antagonist. It blocks the action of serotonin at 5-HT3 receptors in the chemoreceptor trigger zone (CTZ) and gastrointestinal tract, thereby preventing nausea and vomiting. Dextrose provides caloric support.
100 mg orally once daily, or 1.8 mg/kg (maximum 100 mg) intravenously over 15 minutes once daily.
4 mg IV or IM every 8 hours as needed; for prevention of chemotherapy-induced nausea and vomiting, 0.15 mg/kg IV up to 16 mg per dose, infused over 15 minutes, given 30 minutes before chemotherapy, then repeat at 4 and 8 hours after first dose, or as a single 32 mg IV dose over 15 minutes immediately before chemotherapy.
None Documented
None Documented
The terminal elimination half-life is approximately 5-7 hours in normal adults, but may be prolonged in patients with hepatic impairment (up to 11 hours) or severe renal impairment.
Terminal elimination half-life is approximately 3–4 hours in adults, though may be prolonged to 5–8 hours in severe hepatic impairment (Child-Pugh class C) or elderly patients.
Approximately 70% of the dose is excreted in urine (mostly as metabolites, with less than 10% as unchanged drug) and about 20% in feces via biliary elimination.
Primarily hepatic metabolism (~95%) via CYP1A2, CYP2D6, and CYP3A4; less than 10% excreted unchanged in urine. Fecal excretion accounts for ~20% of metabolites.
Category C
Category C
Antiemetic (5-HT3 Antagonist)
Antiemetic (5-HT3 Antagonist)